Slides from Paris Melanoma Meeting addressing ipi combos

Covering much of the same territory as my prior post  http://chaoticallypreciselifeloveandmelanoma.blogspot.com/2014/09/weber-presentation-on-present-ipi.html
However, this presentation is in slide form, allowing you to see the data a bit differently.  Here is a synopsis with presentation linked below:

For ipi and nivo...combo or sequential:

• 43% ORR with 17% CR's and 82% in remission for all concurrent ipi/nivo patients
• 62% grade 3-4 AEs (LFTs, lipase, amylase, rash, colitis)
• BRAF status, PD-L1 tumor staining NOT associated with response
• Response in sequential patients associated WITH ipi PK levels prior to starting anti-PD1
• Concurrent 2 yr OS 79% = "IMPRESSIVE" 

Eval of T-VEC (Talmogene Laherparepvec) and ipi combo:

• Unresected, untreated Stage IIIB/IV, 18 patients
• 4 CR, 6 PR, 3 SD, ORR = 56%
• Only 3 grade 3-4 AEs from ipi
• Results may address the hypothesis that T-VEC may prime an immune response amplified by ipi

INCBO24360 and ipi:

• Target inhibition of IDO achieved at 25-50mg BID
• 33% RR and 33% stable disease
• Toxicity = increased LFTs
• Immunotherapy naive patients did best
• 10 of 12 patients required no further therapy

Nivo in patients naive to OR progressed on ipi:

• NO diff between ORR, PFS, and OS between ipi naive and ipi refractory patients [This is different from what studies have shown with Keytruda! More info on above post.]
• High pretreatment MDSC (myeloid derived suppressor cells) increases in T-regs associated with poor outcome [better explanation of this on blog post linked above]
• Perhaps combining anti-PD1 with MDSC or T-reg depletion would make it more effective

Paris Melanoma Meeting July 2014

Wishing all the ratties my very best! - c